ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

pentanedioic acid imidazolyl ethanamide

Also written as “Ingavirin”, “Ingavirin, capsules, 90 mg” and “Ingavirin®”.

Its studies are mostly in Influenza, Human · Common Cold · COVID-19 · Breast Neoplasms, led by 2 companies.

Drug pagePentanedioic acid imidazolyl ethanamide: every studyAll 8 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Apr 26, 201710 company-led studies, 2 open or runningNext primary completion: Dec 31, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Valenta Pharm JSCits history only92 open or runningphase 4since Apr 26, 2017Dec 22, 2015Dec 31, 2027phase 1 · NCT07645534
Myelo Therapeutics10 open or runningphase 2since Feb 23, 2016Feb 23, 2016none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Myelo Therapeutics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 23, 2016First study: phase 2 study in Breast NeoplasmsFirst studyNCT02692742 · 137 enrolled · Germany

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study Myelo Therapeutics leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02692742Breast Neoplasms · Germany2CompletedNov 2017137

How it is read

Names in the registry

  • “Ingavirin”, 3 entries
  • “Ingavirin, capsules, 90 mg”, 1 entry
  • “Ingavirin®”, 1 entry
  • “Ingavirin®, syrup, 30 mg/5 ml”, 1 entry
  • “Ingavirin®, 90 mg capsules”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.